tetano
Editor, Senior Moderator
Mod Rheumatol
. 2021 Oct 18;roab056.
doi: 10.1093/mr/roab056. Online ahead of print.
Clinical course of COVID-19 infection in paediatric familial Mediterranean fever patients
Ummusen Kaya Akca[SUP] 1 [/SUP], Seher Sener[SUP] 1 [/SUP], Zeynep Balık[SUP] 1 [/SUP], Sibel Gurlevik[SUP] 2 [/SUP], Pembe Derin Oygar[SUP] 2 [/SUP], Erdal Atalay[SUP] 1 [/SUP], Muserref Kasap Cuceoglu[SUP] 1 [/SUP], Ozge Basaran[SUP] 1 [/SUP], Ezgi Deniz Batu[SUP] 1 [/SUP], Ozlem Teksam[SUP] 3 [/SUP], Yelda Bilginer[SUP] 1 [/SUP], Yasemin Ozsurekci[SUP] 2 [/SUP], Seza Ozen[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: To evaluate the course of coronavirus-19 (COVID-19) infection in paediatric familial Mediterranean fever (FMF) patients and to investigate the risk factors for COVID-19 infection.
Methods: Medical records of 100 consecutive paediatric FMF patients and their COVID-19 infection status were evaluated. Age- and gender-matched control group consisted of 51 patients with positive results for severe acute respiratory syndrome coronavirus 2.
Results: Twenty-five of 100 paediatric FMF patients were detected to have COVID-19 infection. A history of contact with a COVID-19 case was present in ∼95% of patients in both the FMF and control groups with COVID-19 infection. Asymptomatic infection was detected in two patients in the paediatric FMF group (8.0%) and 17 patients in the control group (33.3%) (P = .017). Mild disease was observed in 23 paediatric FMF patients (92.0%) and 28 control patients (54.9%) (P = .001), whereas moderate disease was present in only 6 control patients (11.7%) (0 vs 11.7%, P = .074). Severe or critical disease was not observed in any patients.
Conclusion: Paediatric FMF patients receiving colchicine had no moderate COVID-19 disease compared to the control group. We suggest that colchicine use may tune down the severity of the disease even if it does not prevent COVID-19 infection.
Keywords: COVID‐19 infection; Familial Mediterranean fever; children; colchicine; coronavirus.
. 2021 Oct 18;roab056.
doi: 10.1093/mr/roab056. Online ahead of print.
Clinical course of COVID-19 infection in paediatric familial Mediterranean fever patients
Ummusen Kaya Akca[SUP] 1 [/SUP], Seher Sener[SUP] 1 [/SUP], Zeynep Balık[SUP] 1 [/SUP], Sibel Gurlevik[SUP] 2 [/SUP], Pembe Derin Oygar[SUP] 2 [/SUP], Erdal Atalay[SUP] 1 [/SUP], Muserref Kasap Cuceoglu[SUP] 1 [/SUP], Ozge Basaran[SUP] 1 [/SUP], Ezgi Deniz Batu[SUP] 1 [/SUP], Ozlem Teksam[SUP] 3 [/SUP], Yelda Bilginer[SUP] 1 [/SUP], Yasemin Ozsurekci[SUP] 2 [/SUP], Seza Ozen[SUP] 1 [/SUP]
Affiliations
- PMID: 34897503
- DOI: 10.1093/mr/roab056
Abstract
Objective: To evaluate the course of coronavirus-19 (COVID-19) infection in paediatric familial Mediterranean fever (FMF) patients and to investigate the risk factors for COVID-19 infection.
Methods: Medical records of 100 consecutive paediatric FMF patients and their COVID-19 infection status were evaluated. Age- and gender-matched control group consisted of 51 patients with positive results for severe acute respiratory syndrome coronavirus 2.
Results: Twenty-five of 100 paediatric FMF patients were detected to have COVID-19 infection. A history of contact with a COVID-19 case was present in ∼95% of patients in both the FMF and control groups with COVID-19 infection. Asymptomatic infection was detected in two patients in the paediatric FMF group (8.0%) and 17 patients in the control group (33.3%) (P = .017). Mild disease was observed in 23 paediatric FMF patients (92.0%) and 28 control patients (54.9%) (P = .001), whereas moderate disease was present in only 6 control patients (11.7%) (0 vs 11.7%, P = .074). Severe or critical disease was not observed in any patients.
Conclusion: Paediatric FMF patients receiving colchicine had no moderate COVID-19 disease compared to the control group. We suggest that colchicine use may tune down the severity of the disease even if it does not prevent COVID-19 infection.
Keywords: COVID‐19 infection; Familial Mediterranean fever; children; colchicine; coronavirus.